XML 48 R42.htm IDEA: XBRL DOCUMENT v3.19.3
Restructuring, Strategic Transaction and Integration Restructuring, Strategic Transaction and Integration (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2019
Sep. 30, 2018
Sep. 30, 2019
Sep. 30, 2018
Restructuring and Related Activities [Abstract]        
Restructuring, Impairment, and Other Activities Disclosure [Text Block]     Restructuring, Strategic Transaction and Integration

Restructuring and strategic transaction and integration expenses were $8.0 million and $69.4 million for the three and nine months ended September 30, 2019, respectively, as compared to $24.0 million and $64.3 million for the three and nine months ended September 30, 2018, respectively.

Restructuring

During the three and nine months ended September 30, 2019, restructuring charges were $0.8 million and $8.4 million, respectively, primarily related to severance and facility closure costs. These charges are primarily related to a one-time charge to move our U.S. pump service depot to our existing Salt Lake City facility and other plant restructuring. Restructuring charges are included in the restructuring, strategic transaction and integration line item in our condensed consolidated statement of operations.

During the year ended December 31, 2015, we incurred restructuring charges related to an agreement with Dr. Lopez, a member of our Board of Directors and a former employee in our research and development department, pursuant to which we bought out Dr. Lopez's right to employment under his then-existing employment agreement. The buy-out, including payroll taxes, is paid in equal monthly installments until December 2020.
    
The following table summarizes the details of changes in our restructuring-related accrual for the period ended September 30, 2019 (in thousands):

 
Accrued Balance January 1, 2019
 
Charges
Incurred
 
Payments
 
Accrued Balance
September 30, 2019
Severance pay and benefits
$
677

 
$
5,349

 
$
(1,900
)
 
$
4,126

Employment agreement buyout
739

 
—

 
(279
)
 
460

Facility closure expenses
—

 
3,095

 
(595
)
 
2,500

 
$
1,416

 
$
8,444

 
$
(2,774
)
 
$
7,086



Strategic transaction and integration expenses

We incurred and expensed $7.2 million and $61.0 million in strategic transaction and integration expenses during the three and nine months ended September 30, 2019, respectively, as compared to $23.5 million and $61.3 million during the three and nine months ended September 30, 2018, respectively. The strategic transaction and integration expenses during the three months ended September 30, 2019 and the three and nine months ended September 30, 2018 were primarily related to the integration of the Hospira Infusion Systems ("HIS") business acquired in 2017 from Pfizer. The nine months ended September 30, 2019 also included a one-time strategic supply chain restructuring charge of $22.1 million, which reduces our contracted commitments to our third party manufacturer and charges related to our Pfizer separation costs and clean-up, which included a $12.7 million non-cash write-off of related assets. 		 
Restructuring, strategic transaction and integration $ 8.0 $ 24.0 $ 69.4 $ 64.3
Restructuring Costs $ 0.8   $ 8.4